• Cannabis Bioscience International Holdings completed a patent-ready melanoma R&D program focused on cannabinoid science, oncology biology, cellular stress, and epigenetic regulation.
• Work targets interactions between the endocannabinoid system and epigenetic mechanisms tied to tumor behavior, immune response, and aging-related stress.
• Program feeds an IP portfolio of 25 finalized patent applications, including 10 already filed with the USPTO.
• Management framed the milestone as positioning for licensing, clinical collaborations, manufacturing relationships, and strategic partnerships.
• Company cited the June 29, 2026 start of a DEA hearing on proposed marijuana rescheduling as a potential tailwind for research conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannabis Bioscience International Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606010700NEWSFILECNPR____20260601_299514_1) on June 01, 2026, and is solely responsible for the information contained therein.